Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
P144 Cream Extension for Skin Fibrosis in Systemic Sclerosis
NCT00781053Phase 2Completed
- Sponsor
- ISDIN
- Start
- Jul 2008
- Primary completion
- Dec 2010
- Modality
- Recombinant Proteins and Enzymes, Modified Peptides, Native Peptides
- Countries
- 6
01
Overview
Phase 2, open-label, single-arm trial of disitertide in systemic sclerosis (SSc), sponsored by ISDIN. Primary endpoint: Incidence of Treatment Related Adverse Events at 6 months. Started Jul 2008; status: completed.
02
Drugs
disitertide
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT00781053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00781053.